The levels of several miRNAs and their corresponding target mRNAs are changed under pathology and in the course of AD, affecting processes critical to the disease development and progression such as APP production, Tau phosphorylation and Aβ production (Fig. 2) [140]. The gene discussed is MAPT; the disease is Alzheimer disease.